- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
- Device
- Lead sponsor
- Bright Cloud International Corp
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- North Brunswick, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,988
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hearing Loss, Deafness, Hearing Disorders in Children, Hearing Impaired Children, Speech Therapy, Speech Disorders in Children, Literacy
- Interventions
- Speech Language Therapy, Digital Software Application
- Behavioral
- Lead sponsor
- Prasanth Pattisapu
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Dementia, Alzheimer Disease, Infections
- Interventions
- TRAIN AD 2.0
- Behavioral
- Lead sponsor
- Hebrew SeniorLife
- Other
- Eligibility
- 60 Years to 106 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis
- Interventions
- [18F]-PI2620 PET scan
- Diagnostic Test
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Interventions
- AXS-05 (dextromethorphan-bupropion)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 21
- States / cities
- Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
- Interventions
- GammaSense Stimulation System (non-invasive, non-significant risk)
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Newton, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- NGP 555
- Drug
- Lead sponsor
- NeuroGenetic Pharmaceuticals Inc
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Alzheimer's Disease
- Interventions
- T-817MA, Placebo
- Drug
- Lead sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 28 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
- Conditions
- Alzheimer Disease, Dementia, Hearing Loss, Cognitive Impairment
- Interventions
- HEARS-NPS device, HEARS-NPS program
- Device · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mild Cognitive Impairment (MCI), Mild Alzheimer Disease, Memory Deficits
- Interventions
- home-based self-administered interactive exercise
- Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Logopenic Progressive Aphasia, Amnestic Symptoms
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- LY451395, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Costa Mesa, California • Hamden, Connecticut + 14 more
- Conditions
- Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
- Interventions
- Fareon device
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease, Healthy Volunteer
- Interventions
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Cognitive Decline, Alzheimer Disease
- Interventions
- [18F]AV-1451
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
- Interventions
- Renew NCP-5
- Device
- Lead sponsor
- Renew Research, LLC
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
- Conditions
- Alzheimer's Disease
- Interventions
- Dimebon tablet for oral administration
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Encino, California • Los Alamitos, California + 2 more
- Conditions
- Alzheimer Disease
- Interventions
- P-tau217 Test
- Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 3,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2033
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Aphasia, Primary Progressive Aphasia, Dementia, Communication, Alzheimer Disease
- Interventions
- Communication Bridge™
- Behavioral
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Parkinson's Disease
- Interventions
- Detailed motor testing, including FoG, in PD subjects
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer Disease
- Interventions
- COR388, Placebo
- Drug
- Lead sponsor
- Cortexyme Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- San Diego, California • Orlando, Florida • Cincinnati, Ohio
- Conditions
- Dementia
- Interventions
- Sleep Education Program
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Early Alzheimer's Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more